Neurocrine Biosciences 주식 (NASDAQ: NBIX)

에 대한 최신 뉴스 Neurocrine Biosciences (NASDAQ:NBIX) 주식

NEUROCRINE BIOSCIENCES INC

Neurocrine Biosciences

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Mclean,,Va,-,April,20,,2019:,Microstrategy,-,Sign,At

Equities

Large Cap

News

Movers

ERIC

FANG

INSM

MSTR

NBIX

SMMT

TTAN

일라이 릴리, 스트레티지 등 지난주 부활절 주간에 급등한 대형주 10종목 (4월 14~18일)

paypal-shutter2

Trading Ideas

AVTR

ILMN

MRNA

PYPL

SWKS

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 스카이웍스 솔루션(NASDAQ:SWKS)의 주식은 회사가 1분기 실적을 발표하고 2분기 가이던스를 예상치 이하로 제시한 후 25.99% 하락했다. 애널리스트들은 주가 전망을 수정했다.

에스티 로더, 모더나 및 페이팔 등 지난주 하락한 10개의 대형주 (2월 3일-7일)

DRI, Darden

BIRK

CHWY

DOCS

KVYO

TEVA

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 테바 파마수티컬스(NYSE:TEVA)의 주식은 회사와 사노피 SA(NASDAQ:SNY)가 궤양성 대장염 및 크론병에 대한 두바키투그(Duvakitug)의 2b상 시험에서 1차 평가변수가 충족되었다고 발표한 후 주가는 33.88% 상승했다.

테바, 리 오토 및 다덴 레스토랑이 지난주 최고 성과를 보여준 10개 대형주 중 일부 (12월 16-20일)

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences Inc

Providing a diverse range of perspectives from bullish to bearish, 16 analysts have published ratings on Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $152.0, a high estimate of $185.00, and a low estimate of $115.00. Highlighting a 1.89% decrease, the current average has fallen from the previous average price target of $154.93. 
<img src="https://www.benzinga.com/files/images/story/2025/1748894478_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Neurocrine Biosciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$154.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$165.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$115.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$152.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$139.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$158.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$168.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$138.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$137.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$137.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$184.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$185.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Neurocrine Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Neurocrine Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>Discovering Neurocrine Biosciences: A Closer Look</h2>
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
<h3>A Deep Dive into Neurocrine Biosciences's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Neurocrine Biosciences's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 11.12%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Neurocrine Biosciences's net margin is impressive, surpassing industry averages. With a net margin of 1.38%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's ROE excels beyond industry benchmarks, reaching 0.31%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.21%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.18, Neurocrine Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Expectations For Neurocrine Biosciences's Future

RBC Capital analyst Brian Abrahams reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Outperform and maintains $145 price target.

Price Target

Reiteration

RBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $145 Price Target

<ul>
<li>KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on tardive dyskinesia using multiple clinically validated scales</li>
<li>Patients taking INGREZZA reported robust and clinically meaningful improvements in physical, social and emotional functioning</li>
<li>Improvements were seen as early as Week 4 after initial treatment with the lowest INGREZZA dose and sustained through Week 24</li>
<li>Even patients with milder uncontrolled movement severity were negatively impacted by their tardive dyskinesia at baseline and demonstrated meaningful improvements in tardive dyskinesia impact with INGREZZA treatment</li>
</ul>
SAN DIEGO, June 2, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439241-1&amp;h=2727807877&amp;u=https%3A%2F%2Fwww.neurocrine.com%2F&amp;a=Neurocrine+Biosciences%2C+Inc.">Neurocrine Biosciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) today announced new data from the Phase 4 KINECT-PROTM open-label study demonstrating robust and sustained improvements in physical, social and emotional functioning in patients with tardive dyskinesia taking once-daily INGREZZA&#xAE; (valbenazine) capsules. KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment, specifically INGREZZA, on tardive dyskinesia using multiple clinically validated scales, including the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439241-1&amp;h=1411550016&amp;u=https%3A%2F%2Fjpro.springeropen.com%2Farticles%2F10.1186%2Fs41687-023-00679-4&amp;a=Tardive+Dyskinesia+Impact+Scale">Tardive Dyskinesia Impact Scale</a>. The Tardive Dyskinesia Impact Scale is the only patient-reported outcome instrument designed for and validated in tardive dyskinesia patients that measures the physical, social and emotional impact of the involuntary movements of the condition. These results were presented at 2025 Psych Congress Elevate in Las Vegas.

Neurocrine Biosciences Announces New Data From Phase 4 KINECT-PROTM Open-Label Study Showing Robust, Sustained Improvements In Physical, Social And Emotional Functioning In Patients With Tardive Dyskinesia Taking Once-Daily INGREZZA Capsules

Biotech

General

Neurocrine Biosciences Announces New Data From Phase 2 Study Of Nbi-1117568 In Adults With Schizophrenia At American Society Of Clinical Psychopharmacology 2025

A large exercise of company stock options by CHARLES KEVIN GORMAN, Board Member at Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) was disclosed in a new SEC filing on May 22, as part of an insider exercise.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000914475/000091447525000132//Archives/edgar/data/914475/000091447525000132/0000914475-25-000132-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that GORMAN, Board Member at Neurocrine Biosciences, a company in the Health Care sector, just exercised stock options worth 0 shares of NBIX stock with an exercise price of $0.0.
Neurocrine Biosciences shares are trading, exhibiting down of 0.0% and priced at $119.12 during Friday's morning. This values GORMAN's 0 shares at $0.
<h3>About Neurocrine Biosciences</h3>
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
<h3>Neurocrine Biosciences: Delving into Financials</h3>
Revenue Growth: Over the 3 months period, Neurocrine Biosciences showcased positive performance, achieving a revenue growth rate of 11.12% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: Achieving a high gross margin of 98.39%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Neurocrine Biosciences's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.08.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.18.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 40.38 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 5.11 is above industry norms, reflecting an elevated valuation for Neurocrine Biosciences's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 20.18, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000914475">Check Out The Full List Of Neurocrine Biosciences's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Decision Making Waves At Neurocrine Biosciences: CHARLES KEVIN GORMAN Exercises Options, Realizing $0

One-Year Data Show Lasting Reductions in Glucocorticoid Doses and Improvements in Clinical Outcomes with CRENESSITY&#x2122; (crinecerfont) in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
SAN DIEGO, May 16, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4429374-1&amp;h=3224598362&amp;u=https%3A%2F%2Fwww.neurocrine.com%2F&amp;a=Neurocrine+Biosciences%2C+Inc.">Neurocrine Biosciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) today announced&nbsp;it will present new data from the Phase 3 CAHtalyst&#x2122; Pediatric study showing lasting reductions in&nbsp;glucocorticoid doses in pediatric patients with classic congenital adrenal hyperplasia who received <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4429374-1&amp;h=3320559394&amp;u=https%3A%2F%2Fwww.crenessity.com%2F&amp;a=CRENESSITY%E2%84%A2+(crinecerfont)">CRENESSITY&#x2122; (crinecerfont)</a>&nbsp;for up to one year. In addition, the study showed that for patients on CRENESSITY, adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione remained below baseline levels, despite substantially decreased glucocorticoid doses. Results also showed improvements in clinical outcomes, including body mass index and insulin resistance. These data will be presented at the Pediatric Endocrine Society (PES) 2025 Annual Meeting&nbsp;taking place from May 15-18, 2025, in National Harbor, MD. &nbsp;

Neurocrine Biosciences To Present One-Year Data From Phase 3 CAHtalyst Pediatric Study At PES 2025, Showing Lasting Reductions In Glucocorticoid Doses Who Received CRENESSITY

<ul>
<li>Patients Treated with INGREZZA&#xAE; (valbenazine) Capsules Reported Continued Improvements in Functional and Health-Related Quality of Life Measures</li>
<li>Findings Presented at 2025 International Society for Pharmacoeconomics and Outcomes Research Conference</li>
</ul>
SAN DIEGO, May 16, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4429144-1&amp;h=3622899937&amp;u=https%3A%2F%2Fwww.neurocrine.com%2F&amp;a=Neurocrine+Biosciences%2C+Inc.">Neurocrine Biosciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) today announced the presentation of new analyses from a Phase 4 randomized withdrawal study (NCT03891862) showing patients with tardive dyskinesia who received continued treatment with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4429144-1&amp;h=822071139&amp;u=https%3A%2F%2Fwww.ingrezza.com%2F&amp;a=INGREZZA%C2%AE+(valbenazine)+capsules">INGREZZA&#xAE; (valbenazine) capsules</a> reported improvements across functional and health-related quality of life measures. These findings complement recently announced patient-reported outcome data from the Phase 4 <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4429144-1&amp;h=3673751604&amp;u=https%3A%2F%2Fneurocrine.gcs-web.com%2Fnews-releases%2Fnews-release-details%2Fneurocrine-biosciences-reports-patient-reported-outcome-data&amp;a=KINECT-PRO%E2%84%A2+study">KINECT-PRO&#x2122; study</a> of INGREZZA, which was the first of its kind to specifically measure and report clinically meaningful improvements in the impact of tardive dyskinesia. The analyses were presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference in Montreal, Canada.

Neurocrine Biosciences Presents New Phase 4 Analysis Showing INGREZZA Improves Function & Quality Of Life In Tardive Dyskinesia Patients

Presents New Data From The Phase 3 CAHtalyst Adult And Pediatric Studies Of CRENESSITY;  Data Showed That A Substantial Proportion Of Pediatric Patients With Classic Congenital Adrenal Hyperplasia Achieved Physiologic-Range Glucocorticoid Doses And Normal Androstenedione Levels

<ul>
<li>Most Studies Meeting the Literature Review Criteria Found That a Higher Glucocorticoid Dose was Statistically Significantly Associated with Adverse Clinical Outcomes</li>
<li>Findings Presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research Annual Meeting</li>
</ul>

Events

Neurocrine Biosciences Presents Study Showing Relationship Between Higher Glucocorticoid Dose And Adverse Clinical Outcomes

- Data Consistent Across All Patient Subgroups, Including Demographic Subgroups, by Baseline Androstenedione Levels and by Baseline Glucocorticoid Dose
- Findings to be Presented at the 2025 Joint Congress of&nbsp;the European Society for Paediatric Endocrinology&nbsp;and the&nbsp;European Society of Endocrinology

Neurocrine Biosciences Announces New Results From Phase 3 CAHtalyst Pediatric Study

Neurocrine Biosciences Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) stock is trading higher on Tuesday after the company reported better-than-expected <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45206088/neurocrine-biosciences-reports-first-quarter-2025-financial-results-and-reaffirms-2025-financial-g" rel="noreferrer noopener">first-quarter 2025 earnings</a>.
The company on Monday reported adjusted EPS of 70 cents, lower than the $1.20 reported a year ago, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of 54 cents</a>.
Neurocrine reported sales of $572.6 million compared to $515.3 million a year ago, missing the&nbsp;consensus of $559.3 million.
Ingrezza&#8217;s first-quarter 2025 net product sales were&nbsp;$545 million, representing an 8% year-over-year growth, driven by underlying patient demand, including record new patient starts and improved gross-to-net dynamics.
<ul>
<li>Expanded formulary access for Ingrezza significantly improved coverage to include two-thirds of tardive dyskinesia (TD) and Huntington&#8217;s disease Medicare beneficiaries.</li>
<li>William Blair writes, &#8220;Ingrezza sales for the quarter were more resilient than investors had feared given Part D formulary utilization and Teva Pharmaceutical Industries Ltd&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) Austedo competition.&#8221;</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44818760/neurocrine-biosciences-positive-crenessity-physician-survey-turns-this-analyst-bullish" rel="noreferrer noopener">Neurocrine Biosciences&#8217; Positive Crenessity Physician Survey Turns This Analyst Bullish</a>
Crenessity first-quarter net product sales were&nbsp;$14.5 million&nbsp;and included 413 total patient enrollment start forms, reflecting strong initial patient demand with approximately 70% reimbursement coverage for dispensed scripts.
Guidance:&nbsp;Neurocrine Biosciences reaffirms its <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43569079/why-is-neurocrine-biosciences-stock-trading-lower-on-friday" rel="noreferrer noopener">2025 Ingrezza sales guidance</a> of $2.5 billion-$2.6 billion.
Despite headwinds, Ingrezza sales &#8220;avoided a big miss,&#8221; William Blair analyst Myles R. Minter said in a Tuesday research note.
Minter views Ingrezza as &#8220;the gold-standard pharmacotherapy for TD, given its once-daily dosing, no need for long dose titration intervals, and lack of a suicidality and depression FDA black-box warning.&#8221; In addition, the company boasts 14 years of potential future patent protection. 
&#8220;We also view the beat from Crenessity as indicative of a strong sales effort, and although early, we are impressed by the early launch metrics and interest in the orphan disease therapy,&#8221; Minter added.
William Blair <a target="_blank" href="https://www.benzinga.com/quote/NBIX/analyst-ratings" rel="noreferrer noopener">maintains the Outperform rating</a>.
Other analyst reaction:
<ul>
<li>Needham maintains Neurocrine Biosciences with a Buy, raising the price target from $138 to $139.</li>
<li>Canaccord Genuity maintains Neurocrin with a Buy, raising the price target from $158 to $160.</li>
<li>UBS keeps the Buy rating for Neurocrine, raising the price target from $137 to $152.</li>
<li>BMO Capital maintains Neurocrine with a Market Perform, raising the price target from $96 to $115.</li>
<li>Guggenheim maintains Neurocrine with a Buy, raising the price target from $155 to $165.</li>
</ul>
Price Action: NBIX stock is up 14% at $125.07&nbsp;at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45221957/pasithea-therapeutics-drug-shows-tumor-reduction-in-pancreatic-cancer-strong-early-trial-results" target="_blank" rel="noreferrer noopener">Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results</a></li>
</ul>

Analyst Color

Earnings

Guidance

Health Care

Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target

Piper Sandler analyst David Amsellem reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Overweight and lowers the price target from $160 to $154.

Piper Sandler Reiterates Overweight on Neurocrine Biosciences, Lowers Price Target to $154

RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Outperform and raises the price target from $137 to $145.

RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $145

Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and raises the price target from $155 to $165.

Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $165

U.S. stocks were lower, with the Nasdaq Composite falling over 1% on Tuesday.
Shares of FARO Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) rose sharply during Tuesday's session after the company announced it entered into a definitive agreement to be acquired by AMETEK for an enterprise value of <a href="https://www.benzinga.com/quote/FARO">approximately $920 million</a>.
FARO Technologies shares jumped 34.1% to $42.18 on Tuesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares jumped 42% to $132.09.</li>
<li>Diversified Healthcare Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHC#NASDAQ">DHC</a>) rose 28% to $2.80 after the company reported first-quarter financial results and beat its FFO and sales estimates.</li>
<li>EVgo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) gained 28% to $3.55 after the company reported better-than-expected first-quarter sales results and issued FY25 sales guidance with its midpoint above estimates.</li>
<li>ThredUp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) rose 25.4% to $5.57 after the company reported better-than-expected first-quarter results and raised its FY25 sales guidance.</li>
<li>Ameresco, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) gained 18% to $13.72 after the company reported better-than-expected quarterly financial results and issued FY25 guidance with its midpoint above estimates.</li>
<li>Lindblad Expeditions Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIND#NASDAQ">LIND</a>) rose 17.5% to $10.72 after the company reported a first-quarter sales beat and issued FY25 sales guidance with its midpoint above estimates.</li>
<li>Neurocrine Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) gained 12.8% to $123.73 after the company reported better-than-expected first-quarter financial results. Also, Needham maintained a Buy rating on the stock and raised its price target from $138 to $139.</li>
<li>Hims &amp; Hers Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NASDAQ">HIMS</a>) rose 6.2% to $44.49 after the company reported first-quarter financial results. Also, the company issued second-quarter revenue guidance below estimates.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) gained 7.2% to $48.01 following upbeat quarterly results.</li>
<li>Avient Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVNT#NYSE">AVNT</a>) rose 6.4% to $36.19 following quarterly results.</li>
<li>Fresenius Medical Care AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) shares climbed 6.4% to $27.27 after the company reported better-than-expected quarterly financial results.</li>
<li>Aramark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>) rose 6.4% to $36.41 following strong quarterly earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

AMRC

ARMK

AVNT

EVGO

FARO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LIND

TDUP

FARO Technologies, Celanese, Avient, Aramark And Other Big Stocks Moving Higher On Tuesday

BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Market Perform and raises the price target from $96 to $115.

BMO Capital Maintains Market Perform on Neurocrine Biosciences, Raises Price Target to $115

UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and raises the price target from $137 to $152.

UBS Maintains Buy on Neurocrine Biosciences, Raises Price Target to $152

Ratings for Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) were provided by 19 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $162.95, with a high estimate of $185.00 and a low estimate of $137.00. This current average has decreased by 4.65% from the previous average price target of $170.89. 
<img src="https://www.benzinga.com/files/images/story/2025/1746532832_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Neurocrine Biosciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$139.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$158.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$168.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$138.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$137.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$137.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$184.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$185.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$185.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$163.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$148.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$147.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$163.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$179.00</td>
<td>$184.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Neurocrine Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Neurocrine Biosciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>Discovering Neurocrine Biosciences: A Closer Look</h2>
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
<h3>Neurocrine Biosciences: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Neurocrine Biosciences's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 21.84%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Neurocrine Biosciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 16.43%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.88%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Neurocrine Biosciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.84% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.18, Neurocrine Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 19 Analyst Ratings Have To Say About Neurocrine Biosciences

Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and raises the price target from $158 to $160.

Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $160

WIIM

Neurocrine Biosciences shares are trading higher after the company reported better-than-expected Q1 financial results. Also, Needham maintained a Buy rating on the stock and raised its price target from $138 to $139.

Press Releases

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia

Neurocrine Biosciences to Present at Upcoming Investor Conferences in May

Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups

Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia

Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)

Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia

Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting

Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

Management

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia

FATE

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Moderna

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

RBC Capital

Piper Sandler

Guggenheim

BMO Capital

지난주 최고의 실적을 기록한 대형주는 다음과 같다.
<ol>
<li>서비스타이탄(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) 주가는 22.55% 급등했다, 코발트 서비스 파트너스(Cobalt Service Partners)와 전략적 파트너십을 발표한 후 12개 상업적 접근 솔루션 브랜드에<a href="https://www.benzinga.com//node/44817937" target="_blank" rel="noreferrer noopener"> 자사의 사업 관리 소프트웨어</a>를 제공하기로 했다.</li>
<li>서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) 주가는 22.13% 올랐다.</li>
<li>YPF 소시에다드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YPF#NYSE">YPF</a>) 주가는 19.94% 상승했다, HSBC 애널리스트 리야나 양(Liyanna Yang)이 주식을 &#8216;축소&#8217;에서 &#8216;유지&#8217;로 상향 조정하고 <a href="https://www.benzinga.com/quote/ypf/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 21달러에서 33달러로 상향 조정했다.</a></li>
<li>일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) 주가는 16.51% 상승했다, 미국 헬스케어 대기업 일라이 릴리는 <a style="font-size: revert;" href="https://www.benzinga.com//node/44860903">식이요법과 운동만으로</a> 혈당 조절이 불충분한 성인 제2형 당뇨병 환자를 대상으로 위약과 비교한 오포글리프론(orforglipron)의 ACHIEVE-1 임상 3상 시험 결과를 발표했다.</li>
<li>스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) 주가는 16.47% 올랐다. 회사가 <a href="https://www.benzinga.com//node/44789931">일주일 간의 중단</a> 이후 비트코인(CRYPTO:<a href="https://www.benzinga.com/quote/btc-usd">BTC/USD</a>) 구매를 재개할 수도 있다고 시사한 이후였다.</li>
<li>아메리카 모빌NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>) 주가는 15.88% 상승했다, HSBC 애널리스트 마드벤드라 싱(Madhvendra Singh)이 주식을 &#8216;유지&#8217;에서 &#8216;매수&#8217;로 상향 조정하고 <a href="http://benzinga.com/quote/amx/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 15.5달러에서 17.5달러로 상향 조정했다.</a></li>
<li>에릭슨(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) 주가는 1분기 실적을 발표한 후 14.91% 상승했다. 추가로, 회사와 벨 캐나다(Bell Canada)는 <a href="https://www.benzinga.com//node/44823834" target="_blank" rel="noreferrer noopener">네트워크 속도와 효율성을 높이기 위한 AI 기반 링크 적응 테스트</a>에 성공했다고도 발표했다.</li>
<li>인스메드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) 주가는 12.10% 상승했다.</li>
<li>다이아몬드백 에너지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) 주가는 11.76% 급등했다, 트루이스트 증권(Truist Securities) 애널리스트 닐 딘그먼(Neal Dingmann)이 목표주가를 238달러에서 242달러로 상향 조정하고 <a href="https://www.benzinga.com/quote/fang/analyst-ratings" target="_blank" rel="noreferrer noopener">매수 등급을 유지했다</a>.</li>
<li>뉴로크린 바이오사이언시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) 주가는 11.75% 상승했다. 일부 <a href="https://www.benzinga.com//node/44818760" target="_blank" rel="noreferrer noopener">애널리스트가 주식을 상향 조정했다</a>.</li>
</ol>
사진 제공: DCStockPhotography via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 스카이웍스 솔루션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>)의 주식은 회사가 1분기 실적을 발표하고 2분기 가이던스를 예상치 이하로 제시한 후 25.99% 하락했다. 애널리스트들은 <a href="https://www.benzinga.com//node/43540329" target="_blank" rel="noreferrer noopener">주가 전망을 수정</a>했다.
2. 에스티 로더 컴퍼니즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/43462736" target="_blank" rel="noreferrer noopener">2분기 실적을 발표한 후</a> 22.05% 급락했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/el/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 하향 조정</a>했다.
3. 뉴로크린 바이오사이언시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>)의 주식은 회사가 재무 결과를 발표할 때 4분기 매출 <a href="https://www.benzinga.com//node/43544393" target="_blank" rel="noreferrer noopener">예상을 밑돌아</a> 19.23% 하락했다. 또한, HC 웨인라이트와 BofA 증권은는 <a href="https://www.benzinga.com/quote/nbix/analyst-ratings" target="_blank" rel="noreferrer noopener">각각의 주가 전망을 하향 조정</a>했다.
4. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주식은 아마도 상원 재무위원회가 로버트 F. 케네디 주니어의 지명을 상원 본회의로 진전시키기로 투표한 후 17.30% 하락했다.
5. 일루미나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/43544682" target="_blank" rel="noreferrer noopener">4분기 실적을 발표한 후</a> 16.33% 하락했다. 애널리스트들은 <a href="https://www.benzinga.com/quote/ilmn/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 하향 조정</a>했다.
6. 벤처 글로벌(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>)의 주식은 아마도 트럼프 대통령이 석유 생산을 늘리겠다는 공약을 재확인한 후 14.23% 하락했다.
7. 아반토(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>)의 주식은 회사가 4분기 실적을 발표하고 <a href="https://www.benzinga.com//node/43560312" target="_blank" rel="noreferrer noopener">조정 EPS 추정치를 하회한 후</a> 14.01% 하락했다.
8. 페이팔 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>)의 주식은 회사가 4분기 실적을 발표하고 애널리스트들이 <a href="https://www.benzinga.com//node/43475080" target="_blank" rel="noreferrer noopener">주가 전망을 수정한 후</a> 12.72% 하락했다.
9. IDEX 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEX#NYSE">IEX</a>)의 주식은 혼재된 <a href="https://www.benzinga.com//node/43479651" target="_blank" rel="noreferrer noopener">4분기 재무 실적</a>에 따라 12.65% 하락했다. 애널리스트들은 <a href="https://www.benzinga.com/quote/iex/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 하향 조정</a>했다.
10. PTC(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/43509190" target="_blank" rel="noreferrer noopener">1분기 재무 실적을 발표하고 가이던스를 예상치 이하로 제시했으며 2025 회계연도 가이던스를 하향 조정한 후</a> 12.64% 하락했다.
사진 출처: Lets Design Studio via Shutterstock
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ED%8C%94%EB%9E%80%ED%8B%B0%EC%96%B4-%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C-%EC%BB%B4%ED%93%A8%ED%84%B0-%EB%B0%8F-%EC%8A%A4%ED%8F%AC%ED%8B%B0%ED%8C%8C%EC%9D%B4-%EB%93%B1-%EC%A7%80/" target="_blank" rel="noopener">팔란티어, 슈퍼 마이크로 컴퓨터 및 스포티파이 등 지난주 상승한 10개 대형주 (2월 3일-2월 7일)</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 테바 파마수티컬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)의 주식은 회사와 사노피 SA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)가 <a href="https://www.benzinga.com//node/42531132" target="_blank" rel="noreferrer noopener">궤양성 대장염 및 크론병</a>에 대한 두바키투그(Duvakitug)의 2b상 시험에서 1차 평가변수가 충족되었다고 발표한 후 주가는 33.88% 상승했다.
2. 클라비요(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>)의 주식은 12.85% 급등했다.
3. 올리브 가든 모회사 다덴 레스토랑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>)의 주식은 회사가 예상보다 좋은 2분기 EPS와 <a href="https://www.benzinga.com//node/42585797" target="_blank" rel="noreferrer noopener">2025 회계연도 매출 전망</a>을 발표한 후 12.54% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/dri/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
4. 닥시미티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>)의 주식은 10.91% 상승했다. 스티븐스 앤 컴퍼니(Stephens &amp; Co.)가 중립 등급으로 커버리지를 시작하고 <a href="https://www.benzinga.com/quote/docs/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 $55</a>로 제시했다.
5. 버켄스탁 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>)의 주식은 회사가 예상보다 좋은 4분기 재무 결과와 2025 회계연도 가이던스를 발표한 후 9.70% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/42599431" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
6. 자빌(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>)의 주식은 회사가 예상보다 좋은 <a href="https://www.benzinga.com//node/42553094" target="_blank" rel="noreferrer noopener">1분기 EPS와 매출</a>을 발표한 후 7.30% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/jbl/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
7. 뉴로크린 바이오사이언시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>)의 주식은 6.88% 상승했다. FDA가 크레네시티(크리네서폰트, crinecerfont) 캡슐과 경구용 용액을 <a href="https://www.benzinga.com//node/42508449" target="_blank" rel="noreferrer noopener">부신피질호르몬 대체 요법 보조 치료제로 승인</a>했다. 이는 4세 이상의 성인 및 소아 환자의 선천성 부신 효소 결핍증(CAH) 치료에 사용된다.
8. 게임스탑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>)의 주식은 지난 주 6.54% 상승했으며, 이는 3분기 실적의 강세가 지속된 결과이다.
9. 닥터 레디스 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>)의 주식은 6.29% 상승했다.
10. 리 오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>)의 주식은 지난주 6.13% 상승했다.
 
사진 제공: Sundry Photography via Shutterstock


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 8월에 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주식은 8월에 34.89% 하락했다. 이 회사는 <a href="https://www.benzinga.com//node/40602417" target="_blank" rel="noreferrer noopener">10-K 제출을 연기</a>했다.
2. 달러 제너럴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>)의 주식은 30.95% 하락했다. 이 회사는 예상보다 저조한 2분기 실적을 발표했으며, 많은 애널리스트들이 <a href="https://www.benzinga.com//node/40656935" target="_blank" rel="noreferrer noopener">주가 목표를 하향 조정</a>했다.
3. 스냅(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>)의 주식은 27.09% 급락했다. 이 회사는 2분기에 매출이 예상보다 저조하다고 발표하고, <a href="https://www.benzinga.com//node/40132594" target="_blank" rel="noreferrer noopener">애널리스트들이 주가 목표를 대폭 하향 조정</a>했다.
4. 테무의 모회사 PDD 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)의 주식은 24.81% 하락했다. 이 회사가 분기 실적을 발표하고 CEO가 <a href="https://www.benzinga.com/news/earnings/24/08/40548945/temu-parent-pdd-posts-86-q2-topline-growth-stock-drops-after-ceo-flags-upcoming-challenges?_gl=1%2A2quf99%2A_gcl_au%2ANzQ5NDg4Nzg3LjE3MjI5NDg1NTA.%2A_ga%2AMTUwODg0NTczNy4xNzE1MTcxNjk4%2A_ga_V7ZK73W7N0%2AMTcyNTYyNjczNi4xMzIuMS4xNzI1NjQ0MzU2LjAuMC4w" target="_blank" rel="noreferrer noopener">올해 남은 기간에 대한 도전 과제를 강조</a>했다.
5. 인텔(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)의 주식은 24.13% 하락했다. 이 회사는 저조한 분기 실적과 <a href="https://www.benzinga.com//node/40115276" target="_blank" rel="noreferrer noopener">15% 인력 감축 계획</a>을 발표했다.
6. 텐센트 뮤직 엔터테인먼트 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>)의 주식은 21.44% 하락했다. 이 회사는 2분기 매출이 예상보다 저조하다고 발표하고, <a href="https://www.benzinga.com//node/40373910" target="_blank" rel="noreferrer noopener">애널리스트들이 주가 목표를 하향 조정</a>했다.
6. 골드 필드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>)의 주식은 18.99% 하락했다. 이 회사가 오시스코 마이닝(<a href="https://www.benzinga.com//node/40309407" target="_blank" rel="noreferrer noopener">Osisko Mining)</a>을 15억 7천만 달러 현금으로 인수했다고 밝혔다.
8. 찰스 리버 래보래토리즈 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>)의 주식은 18.57% 하락했다. 이 회사는 <a href="https://www.benzinga.com//node/40222523" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">분기 실적</a>에서 글로벌 생명공학 고객들의 수요 추세가 약해지고 있다고 경고했습니다.
9. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주식은 <a href="https://www.benzinga.com//node/40514864" target="_blank" rel="noreferrer noopener">17.81% 하락</a>했다.
10. 뉴로크린 바이오사이언시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>)의 주식은 17.04% 락했습니다. 이는 <a href="https://www.benzinga.com//node/40632561" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">조현병 성인들</a>을 대상으로 한 NBI-1117568(NBI-&#8216;568)의 ​​2상 임상 연구에 대한 톱라인 데이터를 제시했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%96%b4%ed%8e%8c-%ec%87%bc%ed%94%bc%ed%8c%8c%ec%9d%b4-%ea%b7%b8%eb%a6%ac%ea%b3%a0-%ec%8a%a4%ed%83%80%eb%b2%85%ec%8a%a4%eb%8a%94-8%ec%9b%94-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4/" target="_blank" rel="noopener">어펌, 쇼피파이 그리고 스타벅스는 8월 최고 성과를 보여준 10개 대형주 중 일부</a></li>
</ul>
Photo via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

INTC

SMCI

SNAP

인텔, 모더나 그리고 달러 제너럴은 8월 최악의 성과를 보인 10개 대형주 중 일부

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 달러 제너럴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>)의 주식은 회사가 2분기 실적과 매출이 예상보다 저조하게 나타났으며 <a href="https://www.benzinga.com//node/40623595" target="_blank" rel="noreferrer noopener">2024년 가이던스를 하향 조정</a>했다고 발표한 후 32.42% 하락했다. 많은 애널리스트들이 <a href="https://www.benzinga.com//node/40656935" target="_blank" rel="noreferrer noopener">주가 목표를 하향 조정</a>했다.
2. 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/40602417" target="_blank" rel="noreferrer noopener">10-K 제출을 지연할 것이라고 발표</a>한 후 20.21% 하락했다.
3. 옥타(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>)의 주식은 <a href="https://www.benzinga.com//node/40613044" target="_blank" rel="noreferrer noopener">2분기 재무 실적</a> 발표 후 18.69% 하락했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/40625762" target="_blank" rel="noreferrer noopener">회사의 주가 목표를 하향 조정</a>했다.
4. 퓨어 스토리지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/40613896" target="_blank" rel="noreferrer noopener">2분기 재무 실적</a>을 발표한 후 16.88% 하락했다. 애널리스트들이 주가 <a href="https://www.benzinga.com/quote/pstg/analyst-ratings" target="_blank" rel="noreferrer noopener">목표를 하향 조정</a>했다.
5. 뉴로크린 바이오사이언시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>)의 주식은 15.66% 하락했다. 이 회사는 <a href="https://www.benzinga.com//node/40632561" target="_blank" rel="noreferrer noopener">조현병 성인</a>을 대상으로 한 NBI-1117568(NBI-&#8216;568)의 ​​2상 임상 연구에 대한 주요 데이터를 발표했다.
6. 심보틱(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>)의 주식은 16.52% 하락했다. <a href="https://www.benzinga.com//node/40575289" target="_blank" rel="noreferrer noopener">짐 크레이머</a>는 &#8220;그 회사는 당신이 가고 싶은 회사가 아니다. 이번 하락 이후에도 너무 높다&#8221;고 말했다.
7. 달러 트리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>)의 주식은 달러 제너럴이 예상보다 저조한 <a href="https://www.benzinga.com//node/40625537" target="_blank" rel="noreferrer noopener">실적과 2024년 가이던스를 발표</a>한 후 12.18% 하락했다.
8. 테무의 모회사 PDD 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)의 주식은 CEO가 하반기 도전 과제를 강조한 <a href="https://www.benzinga.com//node/40548945" target="_blank" rel="noreferrer noopener">2분기 재무 실적</a> 발표 후 12.80% 하락했다.
9. 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주식은 7.71% 하락했다.
10. 마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)의 주식은 9.76% 하락했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%96%b4%ed%8e%8c-%eb%b0%8f-%eb%aa%bd%ea%b3%a0db%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%97%ac%ec%a4%80-10%ea%b0%9c-%eb%8c%80%ed%98%95/" target="_blank" rel="noopener">어펌 및 몽고DB는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (8월 25일-8월 31일)</a></li>
</ul>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Neurocrine Biosciences

뉴스

에 대한 최신 뉴스 Neurocrine Biosciences (NASDAQ:NBIX) 주식

일요일, 4월 20, 2025

일요일, 2월 09, 2025

일요일, 12월 22, 2024

일요일, 9월 08, 2024

화요일, 9월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌